{"disease":{"id":"viral-respiratory-illnesses","name":"viral respiratory illnesses"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04359680","title":"Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1407,"lead_sponsor_name":"Romark Laboratories L.C.","has_results":true},{"nct_id":"NCT07222670","title":"A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"ENA Respiratory Pty Ltd","has_results":false},{"nct_id":"NCT04343248","title":"Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":190,"lead_sponsor_name":"Romark Laboratories L.C.","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}